Immatics Announces Pricing of $175 Million Public Offering
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.
https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-announces-pricing-175-dollar-million-public-offering